Palvella Therapeutics, Inc.
PVLA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7 | $5 | $4 | $3 |
| G&A Expenses | $4 | $4 | $4 | $2 |
| SG&A Expenses | $4 | $4 | $4 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $10 | $9 | $8 | $4 |
| Operating Income | -$10 | -$9 | -$8 | -$4 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$0 | -$0 | $0 |
| Pre-Tax Income | -$11 | -$9 | -$8 | -$4 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$11 | -$9 | -$8 | -$4 |
| % Margin | – | – | – | – |
| EPS | -1.03 | -0.86 | -3.68 | -0.88 |
| % Growth | -19.8% | 76.6% | -318.2% | – |
| EPS Diluted | -1.03 | -0.86 | -3.68 | -0.88 |
| Weighted Avg Shares Out | 11 | 11 | 2 | 2 |
| Weighted Avg Shares Out Dil | 11 | 11 | 2 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $0 |
| Interest Expense | $2 | $1 | $1 | $1 |
| Depreciation & Amortization | $10 | $0 | $0 | $0 |
| EBITDA | $0 | -$8 | -$7 | -$4 |
| % Margin | – | – | – | – |